［1］Buszman P，Szkróbka I，Gruszka A，et al.Comparison of effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in patients with ischemic cardiomyopathy［J］.Am J Cardiol，2007，99：36-41.［2］Yang JH，Choi SH，Song YB，et al.Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction［J］.Am J Cardiol，2013，112：623-629.［3］Kunadian V，Pugh A，Zaman AG，et al.Percutaneous coronary intervention among patients with left ventricular systolic dysfunction：a review and meta-analysis of 19 clinical studies［J］.Coron Artery Dis，2012，23：469-479.［4］Wijns W，Kolh P，Danchin N，et al.Guidelines on myocardial revascularization Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)；European Association for Percutaneous Cardiovascular Interventions (EAPCI)［J］.Eur Heart J，2010，31：2501-2555.［5］Garcia S，Sandoval Y，Roukoz H，et al.Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease：a meta-analysis of 89，883 patients enrolled in randomized clinical trials and observational studies［J］.J Am Coll Cardiol，2013，62：1421-1431.［6］Pijls NH，Fearon WF，Tonino PA，et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease：2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study［J］.J Am Coll Cardiol，2010，56：177-184.［7］Dangas GD，George JC，Weintraub W，et al.Timing of staged percutaneous coronary intervention in multivessel coronary artery disease［J］.JACC Cardiovasc Interv，2010，3：1096-1099.［8］Kapur NK，Jumean MF.Defining the role for percutaneous mechanical circulatory support devices for medically refractory heart failure［J］.Curr Heart Fail Rep，2013，10：177-184.［9］沈敏，刘兵，王海昌，等.心脏再同步化治疗慢性心衰的短期疗效观察［J］.解放军医学杂志，2008，33(8)：1016-1018.［10］Heldman AW，DiFede DL，Fishman JE，et al.Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy：the TAC-HFT randomized trial［J］.JAMA，2014，311：62-73.［11］曹毅，陈宇，张宁坤，等.自体骨髓单个核细胞移植治疗后重度缺血性心力衰竭患者血浆Apelin水平变化及其临床意义［J］.解放军医学杂志，2011，36(7)：757-760.
